Some information on this page may be available only to Healthcare Professionals. Please

About

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - oncology, cardiovascular, renal and metabolism, as well as respiratory and immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the company on Twitter @AstraZeneca.

See the video about us on Facebook

Branches

1

AstraZeneca Global Commercial | Singapore Marketing Company

10 Kallang Avenue #12-10, Aperia Tower 2, Singapore 339510

Mon—Fri: 9:00 AM—5:30 PM

Key Trials

4 trials shown

Astrazeneca

Astrazeneca

Key trial

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

30 November 2020

This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.

Trial number:
NCT04642469
Trial phase:
3
Overall status:
Recruiting
Study type:
Immunotherapy
Astrazeneca

Astrazeneca

Key trial

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

24 July 2020

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

Trial number:
NCT04494425
Trial phase:
3
Overall status:
Recruiting
Study type:
Targeted therapy
Astrazeneca

Astrazeneca

Key trial

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

17 July 2020

This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery

Trial number:
NCT04385368
Trial phase:
3
Overall status:
Recruiting
Study type:
Immunotherapy
Astrazeneca

Astrazeneca

Key trial

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

25 June 2019

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)

Trial number:
NCT03997123
Trial phase:
3
Overall status:
Recruiting
Study type:
Targeted therapy, Chemotherapy